{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:40:02Z","timestamp":1754152802776,"version":"3.41.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","award":["2023DI008"],"award-info":[{"award-number":["2023DI008"]}],"id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K19499","JP24K18571"],"award-info":[{"award-number":["JP23K19499","JP24K18571"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1245\/s10434-025-17487-3","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:26:05Z","timestamp":1748197565000},"page":"7014-7024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Transcriptomic Signature for Prediction of Response to Adjuvant Chemotherapy in Patients With Stages II and III Gastric Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Kenta","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6964-2726","authenticated-orcid":false,"given":"Keisuke","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Shigeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Tanioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenro","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kinugasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"3","key":"17487_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Global cancer statistics, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229-\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin."},{"key":"17487_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320. https:\/\/doi.org\/10.1056\/NEJMoa072252.","journal-title":"N Engl J Med."},{"key":"17487_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/s1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(14)70473-5.","journal-title":"Lancet Oncol."},{"key":"17487_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/jco.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304. https:\/\/doi.org\/10.1200\/jco.18.01138.","journal-title":"J Clin Oncol."},{"key":"17487_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167\u201392. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","journal-title":"J Natl Compr Canc Netw."},{"key":"17487_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2022;33:1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol."},{"key":"17487_CR7","doi-asserted-by":"publisher","unstructured":"Association JGC. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"17487_CR8","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/jco.20.02914","volume":"39","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Yook JH, Park Y-K, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313. https:\/\/doi.org\/10.1200\/jco.20.02914.","journal-title":"J Clin Oncol."},{"key":"17487_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(21)00297-7.","journal-title":"Lancet Oncol."},{"key":"17487_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"W-L Guan","year":"2023","unstructured":"Guan W-L, He Y, Xu R-H. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16:57. https:\/\/doi.org\/10.1186\/s13045-023-01451-3.","journal-title":"J Hematol Oncol."},{"key":"17487_CR11","doi-asserted-by":"publisher","unstructured":"Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochimica et Biophysica Acta (BBA) Rev Cancer. 2021;1876:188549. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188549.","DOI":"10.1016\/j.bbcan.2021.188549"},{"key":"17487_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102175","volume":"95","author":"E Puliga","year":"2021","unstructured":"Puliga E, Corso S, Pietrantonio F, Giordano S. Microsatellite instability in gastric cancer: between lights and shadows. Cancer Treat Rev. 2021;95:102175. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102175.","journal-title":"Cancer Treat Rev."},{"key":"17487_CR13","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1158\/1078-0432.Ccr-10-2180","volume":"17","author":"JY Cho","year":"2011","unstructured":"Cho JY, Lim JY, Cheong JH, et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011;17:1850\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2180.","journal-title":"Clin Cancer Res."},{"key":"17487_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13148-020-0807-x","volume":"12","author":"Y Peng","year":"2020","unstructured":"Peng Y, Wu Q, Wang L, Wang H, Yin F. A DNA methylation signature to improve survival prediction of gastric cancer. Clin Epigenet. 2020;12:15. https:\/\/doi.org\/10.1186\/s13148-020-0807-x.","journal-title":"Clin Epigenet."},{"key":"17487_CR15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/cac2.12494","volume":"43","author":"S-Q Yuan","year":"2023","unstructured":"Yuan S-Q, Nie R-C, Huang Y-S, et al. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Cancer Comm. 2023;43:1312\u201325. https:\/\/doi.org\/10.1002\/cac2.12494.","journal-title":"Cancer Comm."},{"key":"17487_CR16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/ijms18020308","volume":"18","author":"R Kamps","year":"2017","unstructured":"Kamps R, Brand\u00e3o RD, Bosch BJVD, et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction, and cancer classification. Int J Mol Sci. 2017;18:308.","journal-title":"Int J Mol Sci"},{"key":"17487_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/2159-8290.Cd-14-1118","volume":"5","author":"R Dienstmann","year":"2015","unstructured":"Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov. 2015;5:118\u201323. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-1118.","journal-title":"Cancer Discov."},{"key":"17487_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nm1764","volume":"14","author":"G Finak","year":"2008","unstructured":"Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518\u201327. https:\/\/doi.org\/10.1038\/nm1764.","journal-title":"Nat Med."},{"key":"17487_CR19","doi-asserted-by":"publisher","first-page":"11966","DOI":"10.1038\/srep11966","volume":"5","author":"E Martinez-Ledesma","year":"2015","unstructured":"Martinez-Ledesma E, Verhaak RGW, Trevi\u00f1o V. Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. Sci Rep. 2015;5:11966. https:\/\/doi.org\/10.1038\/srep11966.","journal-title":"Sci Rep."},{"key":"17487_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol."},{"key":"17487_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/sla.0000000000005473","volume":"276","author":"K Okuno","year":"2022","unstructured":"Okuno K, Tokunaga M, Kinugasa Y, Baba H, Kodera Y, Goel A. A transcriptomic liquid biopsy assay for predicting resistance to neoadjuvant therapy in esophageal squamous cell carcinoma. Ann Surg. 2022;276:101\u201310. https:\/\/doi.org\/10.1097\/sla.0000000000005473.","journal-title":"Ann Surg."},{"issue":"1","key":"17487_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biomedicines11010119","volume":"11","author":"K Okuno","year":"2023","unstructured":"Okuno K, Xu C, Pascual-Sabater S, et al. Andrographis reverses gemcitabine resistance through regulation of ERBB3 and calcium-signaling pathway in pancreatic ductal adenocarcinoma. Biomedicines. 2023;11(1):119. https:\/\/doi.org\/10.3390\/biomedicines11010119.","journal-title":"Biomedicines"},{"key":"17487_CR23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/s41467-018-04179-8","volume":"9","author":"SC Oh","year":"2018","unstructured":"Oh SC, Sohn BH, Cheong JH, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018;9:1777. https:\/\/doi.org\/10.1038\/s41467-018-04179-8.","journal-title":"Nat Commun."},{"key":"17487_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant."},{"key":"17487_CR25","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/jco.2011.36.7136","volume":"30","author":"SR Smalley","year":"2012","unstructured":"Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327\u201333. https:\/\/doi.org\/10.1200\/jco.2011.36.7136.","journal-title":"J Clin Oncol."},{"key":"17487_CR26","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/jco.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u201393. https:\/\/doi.org\/10.1200\/jco.2011.36.5908.","journal-title":"J Clin Oncol."},{"key":"17487_CR27","doi-asserted-by":"publisher","first-page":"7286","DOI":"10.1200\/jco.2004.00.2253","volume":"23","author":"CN Chen","year":"2005","unstructured":"Chen CN, Lin JJ, Chen JJ, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol. 2005;23:7286\u201395. https:\/\/doi.org\/10.1200\/jco.2004.00.2253.","journal-title":"J Clin Oncol."},{"key":"17487_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.biopha.2009.06.021","volume":"64","author":"ZY Xu","year":"2010","unstructured":"Xu ZY, Chen JS, Shu YQ. Gene expression profile towards the prediction of patient survival of gastric cancer. Biomed Pharmacother. 2010;64:133\u20139. https:\/\/doi.org\/10.1016\/j.biopha.2009.06.021.","journal-title":"Biomed Pharmacother."},{"key":"17487_CR29","doi-asserted-by":"publisher","first-page":"55343","DOI":"10.18632\/oncotarget.10533","volume":"7","author":"P Wang","year":"2016","unstructured":"Wang P, Wang Y, Hang B, Zou X, Mao JH. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 2016;7:55343\u201351. https:\/\/doi.org\/10.18632\/oncotarget.10533.","journal-title":"Oncotarget."},{"key":"17487_CR30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/1878-0261.12351","volume":"12","author":"X Zhu","year":"2018","unstructured":"Zhu X, Tian X, Sun T, et al. GeneExpressScore Signature: a robust prognostic and predictive classifier in gastric cancer. Mol Oncol. 2018;12:1871\u201383. https:\/\/doi.org\/10.1002\/1878-0261.12351.","journal-title":"Mol Oncol."},{"key":"17487_CR31","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1002\/jcp.29511","volume":"235","author":"K Peng","year":"2020","unstructured":"Peng K, Chen E, Li W, et al. A 16-mRNA signature optimizes recurrence-free survival prediction of stages II and III gastric cancer. J Cell Physiol. 2020;235:5777\u201386. https:\/\/doi.org\/10.1002\/jcp.29511.","journal-title":"J Cell Physiol."},{"key":"17487_CR32","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.Ccr-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-1547.","journal-title":"Clin Cancer Res."},{"key":"17487_CR33","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"17487_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/35067088","volume":"2","author":"S Tsukita","year":"2001","unstructured":"Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285\u201393. https:\/\/doi.org\/10.1038\/35067088.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"17487_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008002","volume":"4","author":"R Agarwal","year":"2009","unstructured":"Agarwal R, Mori Y, Cheng Y, et al. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. PLoS One. 2009;4:e8002. https:\/\/doi.org\/10.1371\/journal.pone.0008002.","journal-title":"PLoS One."},{"key":"17487_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1746-1596-8-133","volume":"8","author":"Z Lin","year":"2013","unstructured":"Lin Z, Zhang X, Liu Z, et al. The distinct expression patterns of claudin-2, -6, and -11 between human gastric neoplasms and adjacent non-neoplastic tissues. Diagn Pathol. 2013;8:133. https:\/\/doi.org\/10.1186\/1746-1596-8-133.","journal-title":"Diagn Pathol."},{"key":"17487_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174476","volume":"12","author":"Y Lu","year":"2017","unstructured":"Lu Y, Jing J, Sun L, et al. Expression of claudin-11, -23 in different gastric tissues and its relationship with the risk and prognosis of gastric cancer. PLoS One. 2017;12:e0174476. https:\/\/doi.org\/10.1371\/journal.pone.0174476.","journal-title":"PLoS One."},{"key":"17487_CR38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384. https:\/\/doi.org\/10.1016\/s1470-2045(20)30109-1.","journal-title":"Lancet Oncol."},{"key":"17487_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/jco.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36:276\u201382. https:\/\/doi.org\/10.1200\/jco.2017.75.5009.","journal-title":"J Clin Oncol."},{"key":"17487_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/s2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6:803\u201315. https:\/\/doi.org\/10.1016\/s2468-1253(21)00196-5.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"17487_CR41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1817323.","journal-title":"N Engl J Med."},{"key":"17487_CR42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/s1470-2045(21)00660-4","volume":"23","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23:248\u201358. https:\/\/doi.org\/10.1016\/s1470-2045(21)00660-4.","journal-title":"Lancet Oncol."},{"key":"17487_CR43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1\u20133 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33:522\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.001.","journal-title":"Ann Oncol."},{"key":"17487_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken A, Mohammadi M. The FGF family: biology, pathophysiology, and therapy. Nat Rev Drug Discov. 2009;8:235\u201353. https:\/\/doi.org\/10.1038\/nrd2792.","journal-title":"Nat Rev Drug Discov."},{"key":"17487_CR45","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.bbrc.2006.08.198","volume":"350","author":"R Shaoul","year":"2006","unstructured":"Shaoul R, Eliahu L, Sher I, et al. Elevated expression of FGF7 protein is common in human gastric diseases. Biochem Biophys Res Comm. 2006;350:825\u201333. https:\/\/doi.org\/10.1016\/j.bbrc.2006.08.198.","journal-title":"Biochem Biophys Res Comm."},{"key":"17487_CR46","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3892\/ijo.2017.3927","volume":"50","author":"T Huang","year":"2017","unstructured":"Huang T, Wang L, Liu D, et al. FGF7\/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1. Int J Oncol. 2017;50:1501\u201312. https:\/\/doi.org\/10.3892\/ijo.2017.3927.","journal-title":"Int J Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17487-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:01:38Z","timestamp":1754150498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17487-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["17487"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17487-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}